Drug intelligence / Profile preview

MK-8876

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-8876 is a small molecule inhibitor targeting the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase at site D. It belongs to the class of benzofuran core inhibitors and demonstrates pan-genotypic activity against various HCV genotypes by binding to multiple subdomains of the NS5B polymerase. The drug was developed for antiviral therapy in hepatitis C infection and reached Phase 1 clinical trials. MK-8876 was originally developed by Merck & Co (Merck Sharp & Dohme)[1][3][4][7][8].

Other names: 2-(4-fluorophenyl)-5-(11-fluoro-6H-pyrido[2',3':5,6][1,3]oxazino[3,4-a]indol-2-yl)-N-methyl-6-[methyl(methylsulfonyl)amino]-3-benzofurancarboxamide

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on MK-8876.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-8876.

Explore the full profile